**INDICATIONS FOR TESTING**
Symptomatic adult with neoplastic disease

Obtain biopsy specimens
- Lesional for histopathology
- Perilesional for Cutaneous Direct Immunofluorescence, Biopsy

Obtain serum specimen for
- Paraneoplastic Pemphigus Antibody Screen

Test for immunobullous diseases
See [Epithelial Antibody-Associated Immunobullous Diseases Testing](#) algorithm

Positive
- Paraneoplastic pemphigus

Negative

**ARUP Lab Tests**
- Cutaneous Direct Immunofluorescence, Biopsy 0092572
- Paraneoplastic Pemphigus Antibody Screen 0092107
- Desmoglein 1 and Desmoglein 3 Antibodies in Pemphigus, IgG 0090649
- Bullous Pemphigoid Antigens (180 kDa and 230 kDa), IgG 0092566

*Patients with paraneoplastic pemphigus may demonstrate serum antibodies to multiple epithelia (simple, columnar, transitional) and against desmoglein 1, 3; desmoplakin 1, 2; envoplakin; periplakin; and/or BP 230 and BP 180; therefore, consider desmoglein 1 and desmoglein 3 antibody IgG testing and bullous pemphigoid antigens, BP 180 and BP 230, IgG antibody testing, along with indirect fluorescent antibody testing on rodent substrates to increase sensitivity.*

*See [Monitoring table](#) in Epithelial Antibody-Associated Immunobullous Diseases Testing topic in ARUP Consult for specific tests for monitoring this disease.*

*Consider antilaminin-332 pemphigoid with strong malignancy association (>30% of patients).*